We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLYB icon
201
Rallybio
RLYB
$85.9M
$12.9K ﹤0.01%
1,675
+12
+0.7% +$101
JVSAR
202
DELISTED
JV SPAC Acquisition Corp. Right
JVSAR
$8.87K ﹤0.01%
30,000
– –
IROHR
203
DELISTED
Iron Horse Acquisitions Corp Right
IROHR
$6.95K ﹤0.01%
25,000
– –
GLSTW
204
DELISTED
Global Star Acquisition, Inc. Warrants
GLSTW
$3.61K ﹤0.01%
120,000
– –
EMCGR
205
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$1.03K ﹤0.01%
13,144
– –
UCFIW
206
CN Healthy Food Tech Group Warrant
UCFIW
$875 ﹤0.01%
25,000
– –
CDT icon
207
CDT Equity Inc
CDT
$2.04M
– –
0
– –
FTIIW
208
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
$462 ﹤0.01%
30,000
– –
EMCGW
209
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$241 ﹤0.01%
18,000
– –
AIMAW
210
DELISTED
Aimfinity Investment Corp I Warrant
AIMAW
$126 ﹤0.01%
18,000
– –
ABEO icon
211
Abeona Therapeutics
ABEO
$393M
– –
-24,322
Closed -$154K
ACAD icon
212
Acadia Pharmaceuticals
ACAD
$4.9B
– –
-23,100
Closed -$355K
ACRS icon
213
Aclaris Therapeutics
ACRS
$851M
– –
-90,000
Closed -$104K
ADXN
214
Addex Therapeutics
ADXN
$7.34M
– –
-1,000
Closed -$9.77K
AGIO icon
215
Agios Pharmaceuticals
AGIO
$1.91B
– –
-21,300
Closed -$946K
AMLX icon
216
Amylyx Pharmaceuticals
AMLX
$2.7B
– –
-220,906
Closed -$1.04M
ANIP icon
217
ANI Pharmaceuticals
ANIP
$1.88B
– –
-1,700
Closed -$101K
APLT
218
DELISTED
Applied Therapeutics
APLT
– –
-8,727
Closed -$54.7K
ARGX icon
219
argenx
ARGX
$54.8B
– –
-110
Closed -$59.6K
ARVN icon
220
Arvinas
ARVN
$568M
– –
-20,400
Closed -$502K
AURA icon
221
Aura Biosciences
AURA
$799M
– –
-73,663
Closed -$656K
AVDL
222
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-80,900
Closed -$1.06M
AZN icon
223
AstraZeneca
AZN
$250B
– –
-350
Closed -$54.5K
BHC icon
224
Bausch Health
BHC
$2.21B
– –
-3,700
Closed -$30.2K
BHVN icon
225
Biohaven
BHVN
$2.17B
– –
-2,637
Closed -$132K
7 8
9
10 11

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.